Analysts Expect Baxter International Inc (BAX) to Post $0.70 EPS
Brokerages expect Baxter International Inc (NYSE:BAX) to post earnings per share (EPS) of $0.70 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Baxter International’s earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.61. Baxter International also reported earnings per share of $0.70 during the same quarter last year. The firm is expected to announce its next earnings report on Thursday, April 25th.
According to Zacks, analysts expect that Baxter International will report full-year earnings of $3.24 per share for the current financial year, with EPS estimates ranging from $3.01 to $3.30. For the next year, analysts expect that the company will post earnings of $3.65 per share, with EPS estimates ranging from $3.51 to $3.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Baxter International.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Baxter International had a net margin of 14.60% and a return on equity of 18.46%. The company had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.80 billion.
In related news, insider Third Point Llc sold 8,000,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $68.62, for a total value of $548,960,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Carole J. Shapazian sold 11,749 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $68.48, for a total transaction of $804,571.52. Following the sale, the director now owns 15,237 shares of the company’s stock, valued at $1,043,429.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,055,348 shares of company stock worth $552,892,722. Insiders own 0.07% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Gantzert Investment Co. LLC ADV bought a new stake in Baxter International during the 4th quarter valued at $25,000. Baldwin Brothers Inc. MA grew its holdings in Baxter International by 904.0% during the 4th quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 452 shares in the last quarter. We Are One Seven LLC purchased a new position in shares of Baxter International in the fourth quarter valued at $34,000. Financial Gravity Companies Inc. bought a new stake in shares of Baxter International during the fourth quarter worth $45,000. Finally, CX Institutional raised its holdings in shares of Baxter International by 705.2% in the fourth quarter. CX Institutional now owns 781 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 684 shares in the last quarter. 83.42% of the stock is currently owned by institutional investors and hedge funds.
Shares of BAX opened at $72.57 on Friday. The company has a market capitalization of $38.38 billion, a P/E ratio of 23.79, a P/E/G ratio of 1.78 and a beta of 0.99. Baxter International has a 1-year low of $61.05 and a 1-year high of $78.38. The company has a current ratio of 2.60, a quick ratio of 1.96 and a debt-to-equity ratio of 0.38.
Baxter International announced that its Board of Directors has authorized a share repurchase plan on Tuesday, November 13th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 6.1% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: Understanding Specialty Certificates of Deposit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.